RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Brainstorm Cell Therapeutics - Stock

Brainstorm Cell Therapeutics Equity 2024

Brainstorm Cell Therapeutics Equity

-4.86 M USD

Ticker

BCLI

ISIN

US10501E2019

WKN

A12BXW

In 2024, Brainstorm Cell Therapeutics's equity was -4.86 M USD, a 60.86% increase from the -3.02 M USD equity in the previous year.

Brainstorm Cell Therapeutics Aktienanalyse

What does Brainstorm Cell Therapeutics do?

Brainstorm Cell Therapeutics Inc is an emerging biotech company based in New York City that focuses on developing novel therapies for the treatment of neurodegenerative diseases. The company was founded in 2002 by a team of leading scientists and experts in the field of stem cell research. Their goal was to advance the development of treatment options for diseases such as ALS (Amyotrophic Lateral Sclerosis), Multiple Sclerosis, and Parkinson's through innovative approaches to stem cell therapy. Brainstorm Cell Therapeutics' business model is based on the unique property of stem cells to differentiate into a variety of cell types and regenerate damaged tissue. The company harnesses this ability to develop tailored stem cell therapies that are customized to meet the specific needs of each patient. By utilizing the potential of stem cells to repair tissue damage and support the body's own healing process. The company is divided into two divisions: therapeutics and diagnostics. The therapeutics division is the core area, focusing on the development of stem cell therapies for the treatment of ALS, Multiple Sclerosis, Parkinson's, and other diseases. The company has developed an approach using autologous stem cells, where stem cells are extracted from the patient's own body to minimize the risk of rejection reactions. The company has already reached Phase II clinical trials and has demonstrated promising results from this innovative technology stem cell therapy for the treatment of ALS, as well as MS and Parkinson's. The diagnostics division of Brainstorm Cell Therapeutics focuses on the development of diagnostic tests to aid physicians in diagnosing patients with neurodegenerative diseases more quickly and accurately. One of the current developments is the NurOwn ALS diagnostic test, which is based on the impact of ALS on the patient's immune system. One of Brainstorm Cell Therapeutics' most well-known products is "NurOwn." This stem cell therapy product is provided to ALS patients. The product utilizes the patient's autologous stem cells to slow the progression of the disease and promote the growth of healthy tissue. It is a personalized therapy, tailored to the specific needs of each patient. The company has already conducted various clinical trials with NurOwn and achieved promising results. Brainstorm Cell Therapeutics is an innovative biotech company focused on the development of stem cell therapies for the treatment of neurodegenerative diseases. The company has already achieved promising results with its therapies and plans to further improve its product range. With a strong scientific team and innovative business model, it is well-positioned to play a leading role in the development of therapies for the treatment of neurodegeneration in the future. Brainstorm Cell Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Brainstorm Cell Therapeutics's Equity

Brainstorm Cell Therapeutics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Brainstorm Cell Therapeutics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Brainstorm Cell Therapeutics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Brainstorm Cell Therapeutics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Brainstorm Cell Therapeutics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Brainstorm Cell Therapeutics Stock

What is the equity of Brainstorm Cell Therapeutics this year?

Brainstorm Cell Therapeutics has equity of -4.86 M USD this year.

What was the equity of Brainstorm Cell Therapeutics compared to the previous year?

The equity of Brainstorm Cell Therapeutics has increased/decreased by 60.86% increased compared to the previous year.

What impact does a high equity have on investors of Brainstorm Cell Therapeutics?

A high equity is advantageous for investors of Brainstorm Cell Therapeutics as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Brainstorm Cell Therapeutics?

A low equity can be a risk for investors of Brainstorm Cell Therapeutics, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Brainstorm Cell Therapeutics affect the company?

An increase in equity of Brainstorm Cell Therapeutics can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Brainstorm Cell Therapeutics affect the company?

A reduction in equity of Brainstorm Cell Therapeutics can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Brainstorm Cell Therapeutics?

Some factors that can affect the equity of Brainstorm Cell Therapeutics include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Brainstorm Cell Therapeutics so important for investors?

The equity of Brainstorm Cell Therapeutics is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Brainstorm Cell Therapeutics take to change the equity?

To change equity, Brainstorm Cell Therapeutics can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Brainstorm Cell Therapeutics pay?

Over the past 12 months, Brainstorm Cell Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Brainstorm Cell Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Brainstorm Cell Therapeutics?

The current dividend yield of Brainstorm Cell Therapeutics is .

When does Brainstorm Cell Therapeutics pay dividends?

Brainstorm Cell Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Brainstorm Cell Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Brainstorm Cell Therapeutics located?

Brainstorm Cell Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Brainstorm Cell Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Brainstorm Cell Therapeutics from 6/11/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/11/2024.

When did Brainstorm Cell Therapeutics pay the last dividend?

The last dividend was paid out on 6/11/2024.

What was the dividend of Brainstorm Cell Therapeutics in the year 2023?

In the year 2023, Brainstorm Cell Therapeutics distributed 0 USD as dividends.

In which currency does Brainstorm Cell Therapeutics pay out the dividend?

The dividends of Brainstorm Cell Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Brainstorm Cell Therapeutics

Our stock analysis for Brainstorm Cell Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Brainstorm Cell Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.